Immunoregulatory protein V‐set and immunoglobulin domain‐containing 4 is overexpressed in patients with endometriosis
article
OA: closed
CC0
Abstract
AIM: V-set and immunoglobulin domain-containing 4 (VSIG4) is a potent negative regulator of T-cell responses and is suggested to regulate antitumor immunity. This study investigates whether VSIG4 is significantly expressed in endometriosis patients and the association between VSIG4 levels and serum cancer antigen (CA)-125 levels, VSIG4 levels and endometriosis severity. METHODS: Tumor tissues and peripheral blood samples were obtained during surgery from 42 endometriotic cyst and 21 nonendometriotic tumor patients. The levels of VSIG4 mRNA, VSIG4 protein expression in tumor tissue and serum soluble VSIG4 concentration were compared between the two groups. After dividing the cohort using the optimized cut-off values obtained by receiver operating characteristic curve analysis, we examined the association between VSIG4 levels and serum CA-125 levels, VSIG4 levels and the factors indicating endometriosis severity. RESULTS: The expressions of VSIG4 mRNA, VSIG4 protein and serum VSIG4 concentration were significantly increased in the endometriotic cyst group compared with the control group (P = 0.001, 0.002 and 0.049, respectively). The optimized VSIG4 cut-off values for endometriosis prediction were 0.71, 0.32 and 144.37 pg/mL, respectively. After cohort division using these values, high VSIG4 levels group showed significantly elevated CA-125 compared with low VSIG4 level group (P = 0.010, 0.043 and 0.039, respectively). There was no association between VSIG4 levels and the factors indicating endometriosis severity. CONCLUSION: The expression of VSIG4 in endometriosis patients is increased compared with nonendometriotic tumor patients, and higher VSIG4 levels are significantly associated with higher serum CA-125 levels. VSIG4 may be importantly involved in the immunological alteration of endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (24)
- Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness via openalex
- Endometriosis: epidemiology and aetiological factors via openalex
- Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer via openalex
- Immunological aspects of endometriosis: a review. via openalex
- Immunology of endometriosis via openalex
- Lymphocytes in Endometriosis via openalex
- New considerations for the pathogenesis of endometriosis via openalex
- Revised American Society for Reproductive Medicine classification of endometriosis: 1996 via openalex
- Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis via openalex
- “What do we know about regulatory T cells and endometriosis? A systematic review” via openalex
- W2082227247 via openalex
- W2113140685 via openalex
- W2612056627 via openalex
- W1128324654 via openalex
- W6737467139 via openalex
- W1523489331 via openalex
- W1993527341 via openalex
- W2041775786 via openalex
- W2049193229 via openalex
- W2068682540 via openalex
- W2070650369 via openalex
- W2071903213 via openalex
- W2078364258 via openalex
- W2081691790 via openalex
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:21:47.975235+00:00
License: CC0
· commercial use OK